2025
Registration and Real-Life Studies on Automated Insulin Delivery Systems
Akturk H, Brown S, Beck R, Sherr J, Bergenstal R, Kovatchev B, Vigersky R, Breton M, Hovorka R, Klonoff D, Garg S. Registration and Real-Life Studies on Automated Insulin Delivery Systems. Diabetes Technology & Therapeutics 2025, 27: s48-s59. PMID: 40590747, DOI: 10.1089/dia.2025.0130.Peer-Reviewed Original ResearchConceptsReal-life studyDiabetes Control and Complications TrialIntensive insulin therapyRegistration studiesAutomated Insulin Delivery SystemsRisk of severe hypoglycemiaMethods:</i></b>Conclusions:</i></b>Long-term beneficial effectsComplications associated with type 1 diabetesGlycemic outcomesMultiple daily injectionsStandard of careHemoglobin A1c valuesDigestive and Kidney DiseasesType 1 diabetesSystematic literature searchAutomated Insulin DeliveryDaily injectionsInsulin therapySevere hypoglycemiaQuality of lifeKidney diseaseNational InstituteComplications TrialRegistration and Real-Life Studies on Automated Insulin Delivery Systems
Akturk H, Brown S, Beck R, Sherr J, Bergenstal R, Kovatchev B, Vigersky R, Breton M, Hovorka R, Klonoff D, Garg S. Registration and Real-Life Studies on Automated Insulin Delivery Systems. Journal Of Diabetes Science And Technology 2025, 19: 924-936. PMID: 40590465, PMCID: PMC12213531, DOI: 10.1177/19322968251334993.Peer-Reviewed Original ResearchConceptsReal-life studyDiabetes Control and Complications TrialIntensive insulin therapyMultiple daily injectionsRegistration studiesAutomated Insulin Delivery SystemsRisk of severe hypoglycemiaLong-term beneficial effectsComplications associated with type 1 diabetesGlycemic outcomesStandard of careAutomated Insulin DeliveryDigestive and Kidney DiseasesType 1 diabetesSystematic literature searchQuality of lifeNational InstituteDaily injectionsInsulin therapySevere hypoglycemiaKidney diseaseHbA1c valuesDrug AdministrationComplications TrialT1D managementCardiovascular and Kidney Outcomes and Mortality With Long-Acting Injectable and Oral Glucagon-Like Peptide 1 Receptor Agonists in Individuals With Type 2 Diabetes: A Systematic Review and Meta-analysis of Randomized Trials.
Lee M, Sattar N, Pop-Busui R, Deanfield J, Emerson S, Inzucchi S, Mann J, Marx N, Mulvagh S, Poulter N, Badve S, Pratley R, Perkovic V, Buse J, McGuire D. Cardiovascular and Kidney Outcomes and Mortality With Long-Acting Injectable and Oral Glucagon-Like Peptide 1 Receptor Agonists in Individuals With Type 2 Diabetes: A Systematic Review and Meta-analysis of Randomized Trials. Diabetes Care 2025, 48: 846-859. PMID: 40156846, DOI: 10.2337/dc25-0241.Peer-Reviewed Original ResearchConceptsGlucagon-like peptide 1 receptor agonistsPeptide 1 receptor agonistsComposite kidney outcomeGLP-1RAAll-Cause MortalityType 2 diabetesKidney outcomesLong-actingOral formulationOutcome trialsHazard ratioReduced incidence of MACEIncidence rates of MACEIncreased risk of severe hypoglycemiaMeta-analysis of randomized trialsLong-acting GLP-1RASystematic review of PubMedWorsening kidney functionRisk of severe hypoglycemiaIncidence of MACERate of MACEEvaluate renal functionAdverse cardiovascular eventsCardiovascular outcome trialsReview of PubMed
2024
Consensus Report on Glucagon-Like Peptide-1 Receptor Agonists as Adjunctive Treatment for Individuals With Type 1 Diabetes Using an Automated Insulin Delivery System
Shah V, Peters A, Umpierrez G, Sherr J, Akturk H, Aleppo G, Bally L, Cengiz E, Cinar A, Dungan K, Fabris C, Jacobs P, Lal R, Mader J, Masharani U, Prahalad P, Schmidt S, Zijlstra E, Ho C, Ayers A, Tian T, Aaron R, Klonoff D. Consensus Report on Glucagon-Like Peptide-1 Receptor Agonists as Adjunctive Treatment for Individuals With Type 1 Diabetes Using an Automated Insulin Delivery System. Journal Of Diabetes Science And Technology 2024, 19: 191-216. PMID: 39517127, PMCID: PMC11571606, DOI: 10.1177/19322968241291512.Peer-Reviewed Original ResearchGlucagon-like peptide-1 receptor agonistsPeptide-1 receptor agonistsGLP-1RA therapyGLP-1RAGLP-1RAsType 1 diabetesReceptor agonistsAdjunctive therapyAbsence of randomized controlled trialsIncreasing prevalence of obesityUS Food and Drug AdministrationRisk of severe hypoglycemiaEffective adjunctive therapyPrevalence of obesityTreatment of T1DFood and Drug AdministrationRandomized Controlled TrialsDiabetic ketoacidosisAdjunctive treatmentMetabolic outcomesSevere hypoglycemiaAutomated Insulin DeliveryConsensus reportDrug AdministrationTherapyRisk of Severe Hypoglycemia After Initiation of Noninsulin Glucose-Lowering Therapies in Adults With Type 2 Diabetes at Moderate Cardiovascular Disease Risk.
McCoy R, Swarna K, Neumiller J, Polley E, Deng Y, Mickelson M, Herrin J. Risk of Severe Hypoglycemia After Initiation of Noninsulin Glucose-Lowering Therapies in Adults With Type 2 Diabetes at Moderate Cardiovascular Disease Risk. Clinical Diabetes 2024, 43: 59-70. PMID: 39829688, PMCID: PMC11739335, DOI: 10.2337/cd24-0007.Peer-Reviewed Original ResearchSodium-glucose cotransporter 2Moderate cardiovascular disease riskRisk of severe hypoglycemiaGlucose-lowering therapyCardiovascular disease riskType 2 diabetesSevere hypoglycemiaSodium-glucose cotransporter 2 inhibitorsDPP-4GLP-1 receptor agonistsGlucagon-like peptide 1Risk of hypoglycemiaDPP-4 inhibitorsDipeptidyl peptidase 4Disease riskAvoidance of hypoglycemiaSulfonylurea therapyReceptor agonistsCotransporter 2Sulfonylurea usePatient populationGLP-1Peptidase 4HypoglycemiaEmergency department
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply